Allogeneic bone marrow transplant

PROCEDURE3 trials

Sponsors

National Heart, Lung, and Blood Institute (NHLBI), Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Conditions

Graft vs Host DiseaseGraft-versus-host DiseaseHematologic NeoplasmLeukemiaLupus ErythematosusMultiple MyelomaMyelodysplastic SyndromeSickle Cell Disease

Phase 1

Nonmyeloablative Conditioning and Transplantation for Patients With Refractory Systemic Lupus Erythematosus (SLE)

TerminatedNCT02080195

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsGraft-versus-host Disease, Lupus Erythematosus

Start: 2016-09-13End: 2017-03-29Updated: 2019-10-02

Phase 2

Non-Myeloablative Bone Marrow Transplant for Patients With Sickle Cell Anemia and Other Blood Disorders

TerminatedNCT00489281

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsSickle Cell Disease

Start: 2008-06-23End: 2018-12-29Updated: 2019-04-17

Unknown Phase

Bone Marrow Transplant Studies for Safe and Effective Treatment of Leukemia

CompletedNCT00001623

National Heart, Lung, and Blood Institute (NHLBI)Graft vs Host Disease, Hematologic Neoplasm, Leukemia +2

Start: 1997-03-27End: 2017-08-03Updated: 2019-12-12

Related Papers

Bone marrow transplantation for sickle cell disease using post-transplantation cyclophosphamide and 400 cGy TBI.

2026-01-22

Effect of increased dose of total body irradiation on graft failure associated with HLA-haploidentical transplantation in patients with severe haemoglobinopathies: a prospective clinical trial.

2019-03-14109 citations

Donor lymphocyte count and thymic activity predict lymphocyte recovery and outcomes after matched-sibling hematopoietic stem cell transplant.

2012-10-1218 citations